Novo Nordisk to buy Cardior Pharma for up to $1 billion
Novo Nordisk A/S bought Cardior Pharmaceuticals for $1 billion to enhance cardiovascular treatments. Cardior's microRNA-targeting therapies aim to improve heart function, aligning with Novo's focus on diabetes and obesity history.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cardiology | Cardiovascular | Diabetes | Eating Disorders & Weight Management | Endocrinology | Heart | Obesity | Pharmaceuticals